γ-glutamyl transferase-to-platelet ratio based nomogram predicting overall survival of gallbladder carcinoma

Table 4 Univariate and multivariate Cox proportional hazard analyses of factors associated with overall survival

	Univariate test			Multivariate test
	HR	95%CI	P value	HR	95%CI	P value
Age, yr
≤ 60	1.000			1.000
> 60	1.722	1.089-2.723	0.020	1.976	1.063-3.675	0.031
Gender
Male	1.000
Female	1.033	0.834-1.278	0.769
Jaundice
No	1.000			1.000
Yes	2.378	1.423-3.977	0.001	1.064	0.462-2.450	0.883
Gallbladder stone
No	1.000
Yes	0.983	0.798-1.211	0.873
Differentiation degree of cancer cells			0.018			0.513
Low	5.583	1.870-16.666	0.002	0.860	0.089-8.327	0.897
Low-medium	3.403	1.162-9.969	0.026	0.414	0.043-4.015	0.447
Medium	3.264	1.134-9.394	0.028	0.366	0.037-3.576	0.388
Medium-high	1.980	0.630-6.226	0.243	0.549	0.057-5.277	0.604
High	2.510	0.807-7.803	0.112	0.421	0.042-4.192	0.461
BMI, kg/m2
≥ 22.5	1.000			1.000
< 22.5	3.128	1.956-5.004	< 0.001	2.776	1.394-5.529	0.004
CEA, ng/mL
≤ 5.30	1.000			1.000
> 5.30	2.485	1.478-4.178	0.001	1.477	0.800-2.726	0.212
CA19-9, U/mL
≤ 47.8	1.000			1.000
> 47.8	3.305	2.079-5.251	< 0.001	1.665	0.840-3.297	0.144
Maximal tumor diameter, cm
≤ 2.90	1.000
> 2.90		0.794-1.833	0.499
TNM stage
I + II	1.000			1.000
III + IV	6.810	2.952-15.711	< 0.001	9.093	0.998-82.830	0.050
GPR
≤ 0.365	1.000			1.000
> 0.365	2.298	1.493-3.537	< 0.001	1.974	1.008-3.867	0.047

BMI: Body mass index; TNM: Tumor–node–metastasis; CEA: Carcinoembryonic antigen; CA 19-9: Carbohydrate antigen 19-9; GPR: Gamma-glutamyl transferase–to–platelet ratio.